Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1
Bagsværd, Denmark, 3 June 2022 – Novo Nordisk today announced headline results from the main…